Piramal Pharma Solutions announces sterile fill/finish programme with Theratechnologies

Drug product material will be used in a first-in-human clinical stud

The Pharma Solutions business of Piramal Pharma, a leading contract development and manufacturing organisation (CDMO), announced that it is providing Theratechnologies with GMP manufacturing of sterile fill/finish drug product to support their developmental product as it enters into a first-in-human clinical study.

The clinical material is being produced at the Piramal Pharma Solutions (PPS) manufacturing site in Lexington, Kentucky, which is recognised globally for its expertise in sterile fill/finish services. It will be used in a Phase I trial for TH1902, Theratechnologies’ lead peptide-drug conjugate (PDC) (docetaxel conjugate). The Phase I trial design includes a dose-escalation study to evaluate the safety, pharmacokinetics, maximum tolerated dose (MTD) and preliminary anti-tumour activity of TH1902 administered once every three weeks in patients with advanced solid tumours refractory to available anti-cancer therapies.

According to Peter DeYoung, CEO, Piramal Pharma Solutions, “Our Lexington team went the extra mile to provide solutions to ensure timely formulation development and production of the material. It’s yet another example of how we are focussed on working with our customers to reduce the burden of disease on patients.”